Ceeto Capital Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.02M | Hold |
33,250
| – | – | 0.62% | 42 |
|
|
2025
Q4 | $1.79M | Sell |
33,250
-1,142
| -3% | -$54.9K | 0.52% | 46 |
|
|
2025
Q3 | $1.55M | Buy |
34,392
+1,142
| +3% | +$53.3K | 0.45% | 48 |
|
|
2025
Q2 | $1.54M | Hold |
33,250
| – | – | 0.54% | 44 |
|
|
2025
Q1 | $2.03M | Hold |
33,250
| – | – | 0.77% | 26 |
|
|
2024
Q4 | $1.88M | Buy |
33,250
+3,000
| +10% | +$168K | 0.69% | 32 |
|
|
2024
Q3 | $1.56M | Buy |
30,250
+1,250
| +4% | +$58.6K | 0.58% | 37 |
|
|
2024
Q2 | $1.2M | Sell |
29,000
-1,900
| -6% | -$85K | 0.47% | 48 |
|
|
2024
Q1 | $1.68M | Buy |
30,900
+1,900
| +7% | +$96.8K | 0.69% | 38 |
|
|
2023
Q4 | $1.49M | Buy |
29,000
+400
| +1% | +$21K | 0.64% | 39 |
|
|
2023
Q3 | $1.66M | Buy |
28,600
+600
| +2% | +$36.8K | 0.8% | 30 |
|
|
2023
Q2 | $1.79M | Buy |
28,000
+500
| +2% | +$33.5K | 0.82% | 26 |
|
|
2023
Q1 | $1.91M | Buy |
27,500
+500
| +2% | +$35.3K | 0.95% | 21 |
|
|
2022
Q4 | $1.94M | Hold |
27,000
| – | – | 1.07% | 18 |
|
|
2022
Q3 | $1.92M | Sell |
27,000
-3,000
| -10% | -$218K | 1.1% | 14 |
|
|
2022
Q2 | $2.33M | Hold |
30,000
| – | – | 1.27% | 10 |
|
|
2022
Q1 | $2.21M | Hold |
30,000
| – | – | 1.01% | 19 |
|
|
2021
Q4 | $1.87M | Hold |
30,000
| – | – | 0.78% | 28 |
|
|
2021
Q3 | $1.79M | Sell |
30,000
-3,000
| -9% | -$198K | 0.84% | 29 |
|
|
2021
Q2 | $2.21M | Hold |
33,000
| – | – | 0.99% | 23 |
|
|
2021
Q1 | $2.1M | Buy |
33,000
+1,000
| +3% | +$62.2K | 1.02% | 20 |
|
|
2020
Q4 | $2M | Hold |
32,000
| – | – | 1.01% | 19 |
|
|
2020
Q3 | $1.93M | Sell |
32,000
-500
| -2% | -$30.1K | 1.08% | 19 |
|
|
2020
Q2 | $1.91M | Hold |
32,500
| – | – | 1.24% | 15 |
|
|
2020
Q1 | $1.81M | Hold |
32,500
| – | – | 1.45% | 12 |
|
|
2019
Q4 | $2.09M | Buy |
32,500
+2,000
| +7% | +$115K | 1.37% | 13 |
|
|
2019
Q3 | $1.55M | Hold |
30,500
| – | – | 1.12% | 22 |
|
|
2019
Q2 | $1.38M | Hold |
30,500
| – | – | 1.02% | 28 |
|
|
2019
Q1 | $1.46M | Buy |
30,500
+1,000
| +3% | +$49.8K | 1.07% | 26 |
|
|
2018
Q4 | $1.53M | Hold |
29,500
| – | – | 1.27% | 21 |
|
|
2018
Q3 | $1.83M | Hold |
29,500
| – | – | 1.26% | 14 |
|
|
2018
Q2 | $1.63M | Hold |
29,500
| – | – | 1.22% | 18 |
|
|
2018
Q1 | $1.53M | Hold |
29,500
| – | – | 1.16% | 20 |
|
|
2017
Q4 | $1.81M | Hold |
29,500
| – | – | 1.29% | 16 |
|
|
2017
Q3 | $1.88M | Buy |
+29,500
| New | +$1.72M | 1.41% | 13 |
|
Other funds holding BMY
VCM
VPM
Ceeto Capital Group's BMY Position: Q1 2026 in Review
Ceeto Capital Group held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 33,250 shares worth $2.02M. The position accounts for 0.62% of the portfolio, ranked #42.
Ceeto Capital Group first reported a position in BMY in Q3 2017 and has held it in 35 quarters since. The position peaked at $2.33M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Ceeto Capital Group held 33,250 shares of Bristol-Myers Squibb worth $2.02M as of Q1 2026.
- Ceeto Capital Group left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.62% of Ceeto Capital Group's portfolio in Q1 2026, its #42 holding.
- Ceeto Capital Group first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 35 quarters since.
- Ceeto Capital Group's Bristol-Myers Squibb position peaked at $2.33M in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Ceeto Capital Group's 13F filing for Q1 2026, filed 14 May 2026.